MEDICINE FOR TREATMENT OF ACUTE MYELOID LEukemia (AML)

摘要

1. A drug for the treatment of acute myeloid leukemia (AML), including a suspension of red blood cells with asparaginase encapsulated in them as an active component. The medicine according to claim 1, wherein one dose of the suspension comprises from 50 to 500 IU of encapsulated asparaginase per kg body weight. The medicine according to claim 1, wherein one dose of the suspension comprises from 50 to 200 IU of encapsulated asparaginase per kg body weight. The medicine according to claim 1, wherein one dose of the suspension comprises from 80 to 170 IU of encapsulated asparaginase per kg body weight. The drug according to any one of paragraphs. 1-4, where the patient is a child, adult or elderly person. 6. The medicament according to claim 5, wherein the patient does not tolerate standard treatment. A method for treating acute myeloid leukemia (AML), comprising administering an effective amount of a suspension of red blood cells with asparaginase encapsulated therein. 8. A method for treating acute myeloid leukemia (AML), comprising administering an effective amount of a suspension of red blood cells with asparaginase encapsulated in them, where one or more doses of the suspension are administered to the patient in the induction phase. A method of treating acute myeloid leukemia (AML), comprising administering an effective amount of a suspension of red blood cells with an asparaginase encapsulated in them, where one or more doses of the suspension are administered to the patient during the treatment phase and where one dose of the suspension comprises from 50 to 500 IU of encapsulated asparaginase per kg body weight .10. The method according to claim 9, wherein one dose of the suspension comprises from 50 to 200 IU of encapsulated asparaginase per kg body weight. The method of claim 9, wherein the single dose of the suspension comprises from 80 to 170 IU of encapsulated asparaginase per kg body weight of those